Bioalmanac
Retatrutide
LY3437943 · triple agonist · GGG tri-agonist
An investigational once-weekly triple agonist acting on the GLP-1, GIP and glucagon receptors. Not approved anywhere.
Storage
- Freeze-dried powder
- Refrigerated at 2–8 °C, protected from light and moisture.
- After mixing
- Refrigerated at 2–8 °C. Do not freeze.
- Long-term, frozen
- Unopened lyophilised powder is stable at −20 °C or colder.
Reconstitution — 10 mg vial, 2000 mcg dose
On a 1 mL U-100 syringe. Check every figure against your own vial before drawing.
| Water added | Concentration | Volume to draw | Units | Doses per vial |
|---|---|---|---|---|
| 1 mL | 10 mg/mL | 0.2 mL | 20 units | 5 |
| 2 mL | 5 mg/mL | 0.4 mL | 40 units | 5 |
| 3 mL | 3.333 mg/mL | 0.6 mL | 60 units | 5 |
| 5 mL | 2 mg/mL | 1 mL | 100 units | 5 |
Dose ranges reported in sources
Descriptions of what sources report, not recommendations.
| Goal | Range | Frequency | Source |
|---|---|---|---|
| Phase 2 starting dose | 2000 mcg | Once weekly | Clinical trial |
| Phase 2 escalation and maintenance arms | 4000–12000 mcg | Once weekly, escalated in steps | Clinical trial |
When to stop
- Severe, persistent abdominal pain radiating to the back. Seek urgent medical care.
- Persistent vomiting or inability to keep fluids down.
- A sustained rise in resting heart rate, palpitations, or chest pain.
- Any allergic response: rash, hives, facial swelling, or difficulty breathing. Seek urgent care.
- If you become pregnant or are planning to.
Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.